10/19/2005 5:10:52 PM
At the request of the Toronto Stock Exchange the Company has been asked to comment on the recent drop in the share price. All corporate developments have been announced and the Company is not aware of anything to cause the drop in the share price.
The Company has been cleared to begin a Pivotal Phase IIb/III trial for Tectin(TM) in moderate to severe inadequately controlled cancer related pain. The trial is expected to start shortly as the process of obtaining Ethics Committee approvals advances. This trial could be the last study before receiving market authorization.
comments powered by